How have OBSV shares performed in 2024?

ObsEva's stock was trading at $0.0350 at the start of the year. Since then, OBSV shares have decreased by 85.7% and is now trading at $0.0050. View the best growth stocks for 2024 here .

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) announced its quarterly earnings data on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.23.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , Dynavax Technologies (DVAX) , Matinas BioPharma (MTNB) , Trevena (TRVN) , Zosano Pharma (ZSAN) , Vaxart (VXRT) , VBI Vaccines (VBIV) , Bionano Genomics (BNGO) and ADMA Biologics (ADMA) .

ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OBSV

ObsEva (OBSV) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free OBSV Stock Alerts

$0.0050

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.0040
▼
$0.0051
50-Day Range: $0.00
▼
$0.08
52-Week Range: $0.08
▼
$2.14

Volume: 66,910 shs
Average Volume: 8.94 million shs
Market Capitalization: $389,855.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Social Media

Get ObsEva alerts:

Ad WealthPress

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

That’s exactly how this expert trader plans to trade his #1 ticker for 2024

About ObsEva Stock (NASDAQ:OBSV)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

OBSV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OBSV Stock News Headlines

April 12, 2024 | americanbankingnews.com

ObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.com

April 3, 2024 | globenewswire.com

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 19, 2024 | globenewswire.com

ObsEva Announces Update on Board of Directors

February 28, 2024 | globenewswire.com

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

February 26, 2024 | benzinga.com

ObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Dates

November 11, 2023 | morningstar.com

ObsEva SA OBSN

November 11, 2023 | morningstar.com

ObsEva SA OBSEF

April 19, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

June 18, 2023 | fool.com

ObsEva (NASDAQ: OBSV)

March 31, 2023 | finance.yahoo.com

ObsEva Files Year End 2022 Financial Statements

March 15, 2023 | finance.yahoo.com

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

March 13, 2023 | markets.businessinsider.com

ObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim Chairman

March 13, 2023 | finance.yahoo.com

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

March 3, 2023 | benzinga.com

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session

March 3, 2023 | investorplace.com

Why Is ObsEva (OBSV) Stock Up 93% Today?

February 24, 2023 | investorplace.com

Why ObsEva (OBSV) Stock Is Down 36% Today

February 24, 2023 | finance.yahoo.com

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

January 12, 2023 | uk.finance.yahoo.com

ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing

December 19, 2022 | finance.yahoo.com

ObsEva Announces Dismissal of Moratorium Proceedings

December 14, 2022 | finance.yahoo.com

ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing

December 1, 2022 | finance.yahoo.com

ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates

December 1, 2022 | finance.yahoo.com

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

October 27, 2022 | finance.yahoo.com

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

October 16, 2022 | finance.yahoo.com

ObsEva SA (OBSV)

October 14, 2022 | markets.businessinsider.com

ObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasiban

October 13, 2022 | finance.yahoo.com

ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo Finance

See More Headlines

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OBSV
CUSIP: N/A
CIK: 1685316
Web: www.obseva.com
Phone: (122) 552-3840
Fax: N/A
Employees: 48
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -416.36%
Return on Assets: -92.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.61
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $20.11 million
Price / Sales: 0.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 0.01

Miscellaneous

Outstanding Shares: 77,971,000
Free Float: 66,743,000
Market Cap: $389,855.00
Optionable: Not Optionable
Beta: 0.68

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

William M. Brown
Chief Executive & Financial Officer
Elke Bestel
VP, Head-Drug Safety & Pharmacovigilance
Katja Buhrer
Chief Strategy Officer

Key Competitors

View All Competitors

OBSV Stock Analysis - Frequently Asked Questions

How have OBSV shares performed in 2024?: ObsEva's stock was trading at $0.0350 at the start of the year. Since then, OBSV shares have decreased by 85.7% and is now trading at $0.0050.
View the best growth stocks for 2024 here.
How were ObsEva's earnings last quarter?: ObsEva SA (NASDAQ:OBSV) announced its quarterly earnings data on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.23.
What other stocks do shareholders of ObsEva own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?: ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of ObsEva?: Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OBSV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial